US-based AirWare Labs says that it has filed patent applications for an intranasal drug delivery system that will include "AirWare Labs' patent-pending disposable sealed cartridge and patent-pending nasal insert system with insufflation plugins, both of which can be filled with medication in powder form." The company currently markets a line of disposable nasal … [Read more...] about Company files patent applications for novel intranasal delivery system
News
Aegis Therapeutics gets patent for intranasal CNS drug delivery
The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, "Intranasal administration of active agents to the central nervous system," to Aegis Therapeutics, the company said. The patent covers, "Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are … [Read more...] about Aegis Therapeutics gets patent for intranasal CNS drug delivery
LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
The Bill and Melinda Gates Foundation has awarded a $2.5 million grant to researchers at Liverpool School of Tropical Medicine (LSTM) for a study to determine the effects of nasal spray flu vaccine on pneumococcal bacteria. The 2-year study, to be conducted in conjunction with the Royal Liverpool University Hospital, will recruit almost 300 volunteers, half of … [Read more...] about LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date
According to Avanir Pharmaceuticals,the FDA has issued a Discipline Review letter in response to the company's NDA for AVP-825 intranasal dry powder sumatriptan requesting that the company "optimize the product-user interface" and conduct additional human factor testing. AVP-825 is delivered using OptiNose's Breath Powdered intranasal delivery device. Although the … [Read more...] about Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date
RespiTech team gets grant for development of inhalable Smartdrops technology
The Australian Research Council has awarded a $521,800 grant to Daniela Traini and Paul Young of the Woolcock Institute's RespiTech group and Patrick Spicer of the University of New South Wales for development of inhalable "Smartdrops" for drug delivery to the lung. The three-year project is designed to develop a microfluidics-based process for creating … [Read more...] about RespiTech team gets grant for development of inhalable Smartdrops technology
Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal
As AstraZeneca completes the acquisition of Almirall's respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca. The deal includes the inhalation R&D company Almirall Sofotec as well as a number of inhalers, including the Eklira/Bretaris/Tudorza aclidinium DPI, the Duaklir Genuair … [Read more...] about Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal
Sales of Zomig nasal spray increase 54%
Impax Laboratories has reported a 19.1% increase in total revenues for the quarter ended September 30, 2014 compared to the third quarter of the prior year. The company attributes a portion of the increase in revenues to a 54% increase in sales of Zomig zolmitriptan nasal spray, which it markets in the US for the treatment of migraine. Impax acquired the rights to … [Read more...] about Sales of Zomig nasal spray increase 54%
Ametek announces availability of MDI tester
Danish instrument manufacturer Ametek Test & Calibration Instruments says that it has worked with "a leading pharmaceutical manufacturer" to develop a semi-automated tester that "detects the firing load and valve breakdown load of one-shot, pressurized MDI canisters." The company's announcement says, "Previously there was no known dedicated testing solution for … [Read more...] about Ametek announces availability of MDI tester
AirFluSal Forspiro approved in three more countries
Accordig to Sandoz, the company has received marketing authorization in Estonia, Latvia and Lithuania for the 50-250 and 50-500 µg dosages of the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD. The inhaler is now approved in 13 European countries, as well as in Mexico and South Korea. Sandoz Head of Global Respiratory Jan-Torsten … [Read more...] about AirFluSal Forspiro approved in three more countries
BMS makes deal for inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis
Bristol-Myers Squibb could pay a total of up to $444 million to acquire Galecto Biotech and its TD139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), plus potential milestones. The newly announced deal includes an option to acquire the company that must be exercised no later than 60 days after completion of a Phase 1b trial of … [Read more...] about BMS makes deal for inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis